Carregant...
Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis
A targeted antidote for reversal of direct factor Xa (FXa) inhibitors is now available for clinical use in the United States, but it is costly and has limited availability. In a systematic review, we evaluated the safety and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) as an al...
Guardat en:
| Publicat a: | Blood Adv |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6341194/ https://ncbi.nlm.nih.gov/pubmed/30658963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018024133 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|